title: Recombinant human erythropoietin treatment may induce antithrombin-III depletion.
authors.forename: T
authors.initials: T
authors.lastname: Arinsoy
authors.forename: O
authors.initials: O
authors.lastname: Ozdemir
authors.forename: N
authors.initials: N
authors.lastname: Arik
authors.forename: O
authors.initials: O
authors.lastname: Ozcebe
authors.forename: U
authors.initials: U
authors.lastname: Yasavul
authors.forename: S
authors.initials: S
authors.lastname: Dündar
authors.forename: C
authors.initials: C
authors.lastname: Turgan
authors.forename: S
authors.initials: S
authors.lastname: Kirazli
authors.forename: S
authors.initials: S
authors.lastname: Cağlar
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000378:metabolism*; D004921:Erythropoietin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood; D008297:Male; D011486:Protein C / Q000378:metabolism; D011994:Recombinant Proteins / Q000009:adverse effects; D006435:Renal Dialysis
chemical_list: D011486:Protein C; D011994:Recombinant Proteins; D004921:Erythropoietin; D000990:Antithrombin III